Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.42% | 23.12% | 2.88% | -47.02% | -68.46% |
| Total Depreciation and Amortization | -6.16% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -3.00% | 45.24% | 42.14% | 46.67% | 74.82% |
| Total Other Non-Cash Items | 55.93% | -1.61% | -20.15% | 31.10% | -170.40% |
| Change in Net Operating Assets | 16.15% | 9.14% | 16.36% | 7.58% | 7.89% |
| Cash from Operations | 100.14% | 20.49% | 11.40% | -0.14% | -44.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.39% | -194.83% | -67.69% | 19.67% | 73.38% |
| Cash from Investing | 26.37% | -194.83% | -67.69% | 19.65% | 65.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 84.69% | 92.93% | -53.09% | -50.95% | -264.47% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -12.52% | -9.58% | -0.73% | -1.33% | 1.79% |
| Other Financing Activities | -0.48% | 13.91% | -11.65% | -11.56% | 11.94% |
| Cash from Financing | 46.21% | 71.03% | -16.14% | 272.88% | -143.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.49% | -120.35% | -1,423.10% | 137.69% | -149.46% |